Integrin-binding small molecules

Details Integrin-binding small molecules Integrin-binding small molecules

2011-04-19

2011-04-19

Weddington, Kevin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S337000

Reexamination Certificate

active

07928113

ABSTRACT:
The present invention relates to compositions containing integrin-binding small molecules. Also disclosed are methods of binding integrins to these small molecules and methods of identifying small molecules binding to integrins.

REFERENCES:
Edmunds, Jeremy, et al., “Derivatives of 5-[[1-(4′-Carboxybenzyl)imidazolyl]methylidene]hydantoins as Orally Active Angiotensin II Receptor Antagonists,” J. Med. Chem., vol. 38, pp. 3759-3771 (1995).
Lesyk et al., “New thiazolidones-4 with pyrazolone-5 substituent as the potential NSAIDs”, Bollettino Chimico Farmaceutico, vol. 137, No. 6, pp. 210-217 (1998) abstract.
Seada et al., “Synthesis and biological activity of some new thiazolidiones”, Indian Journal of Heterocycic Chemistry, vol. 3, No. 2, pp. 81-86 (1993) abstract.
Bhatt et al., Synthesis of anti-HIV, anticancer and antitubercular 4-oxothiazolidines, 2-imino-4-oxo-thiazolidines and their 5-arylidine derivatives, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, vol. 33B, No. 2, pp. 189-192 abstract, (1994).
D. Schrama et al., “Antibody Targeted Drugs as Cancer Therapeutics,”Nature Reviews, vol. 5, pp. 148, pp. 147-159 (2006).
R.W. Wilder, “Integrin Alpha V Beta 3 as a Target for Treatment of Rheumatoid Arthritis and Related Rheumatic Diseases,”ARD Online(www.bmjjournals.com), Sep. 25, 2006.
Falm Eskens, “Angiogenesis Inhibitors in Clinical Development; Where are we now and where are we going?”British Journal of Cancer, vol. 90, pp. 1-7, (2004).
C. Ruegg et al., “Antiangiogenic Peptides and Proteins: From Experimental Tools to Clinical Drugs,”Biochemical et Biophysica Acta1765, pp. 155-177 (2006).
X. Duan et al., “Association of αvβ3 Integrin Expression with the Metastatic Potential and Migratory and Chemotactic Ability of Human Osteosarcoma Cells,”Clinical&Experimental Metastatis, vol. 21, pp. 747-753 (2004).
P. Boissy et al., “Aggregation of Mononucleated Precursors Triggers Cell Surface Expression of αvβ3 Integrin, Essential to Formation of Osteoclast-Like Multinucleated Cells,”Journal of Cell Science, vol. 111, pp. 2563-2574 (1998).
N. Reinmuth et al., “αvβ3 Integrin Antagonist S247 Decreases Colon Cancer Metastatsis and Angiogenesis and Improves Survival in Mice,”Cancer Research, vol. 63, pp. 2079-2087 (2003).
K. Switala-Jelen et al., “The Biological Functions of β3 Integrins,”Folio Biologica(Praha), vol. 50, pp. 143-152 (2004).
J. Albert et al., “Integrin αvβ3 Antagonist Cilengitide Enhances Efficacy of Radiotherapy in Endothelial Cell and Non-Small-Cell Lung Cancer Models,”Int. J. Radiation Oncology Biol. Phys., vol. 65, No. 5, pp. 1536-1543 (2006).
M. Sadeghi et al., “Detection of Injury-Induced Vascular Remodeling by Targeting Activated avB3 Integrin in Vivo,”Circulation(www.circulationaha.org), pp. 84-90, Jul. 6, 2004.
M. Janssen et al., “Tumor Targeting with Radiolabeled αvβ3 Integrin Binding Peptides in a Nude Mouse Model,”Cancer Research, vol. 62, pp. 6146-6151 (2002).
J. Song et al., “In Vivo Characterization of the Integrin β3 as a Receptor for Hantaan Virus Cellular Entry,”Experimental and Molecular Medicine, vol. 37, No. 2., pp. 121-127 (2005).
E. Toschi et al., “HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway,”Molecular Biology of the Cell, vol. 17, pp. 1985-1994 (2006).
R. Sobel et al., “Endothelial Cell Integrin Laminin Receptor Expression in Multiple Sclerosis Lesions,”American Journal of Pathology, vol. 153, No. 2, pp. 405-415 (1998).
S. Shattil et al., “Integrins: Dynamic Scaffolds for Adhesion and Signaling in Platelets,”Blood, vol. 104, No. 6, pp. 1606-1615 (2004).
K. Temming et al., “RGD-Based Strategies for Selective Delivery of Therapeutics and Imaging Agents to the Tumour Vasculature,”Drug Resistance Updates, vol. 8, pp. 381-402 (2005).
V. Engleman et al., “A Peptidomimetic Antagonist of the αvβ3 Integrin Inhibits Bone Resorption In Vitro and Prevents Osteoporosis In Vivo,”J. Cin. Invest. vol. 99, No. 9, pp. 2284-2292 (1997).
M.Shimaoka et al., “Therapeutic Antagonists and Conformational Regulation of Integrin Function,”Nature Reviews(www.nature.com), vol. 2, pp. 703-716, Sep. 2003.
V. Nguyen, “Updates on Bisphosphonates for the Treatment of Osteoporosis: Impact on Future Treatment Strategies,”The Pharmacy&Therapeutics Society, Release Date: Jan. 1, 2005, Expiration Date: Dec. 31, 2005.
D. Schrama et al., “Antibody Targeted Drugs as Cancer Therapeutics,”Nature Reviews, vol. 5, pp. 147-159, Feb. 2006.

Affiliated with

Also associated with

Rating

Integrin-binding small molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Integrin-binding small molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin-binding small molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2640846